Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Advaxis, a biotechnology company developing the next generation of cancer immunotherapies, has announced that it has been issued a significant patent from the Japan Patent Office, entitled, ‘Compositions and Methods for Enhancing Immunogenicity of Antigens’.
Subscribe to our email newsletter
The claims of the patent (patent number 5479918) cover the use of ADXS-HPV for the treatment of late-stage cervical cancer with a term that extends to 2028.
Advaxis CEO Daniel J. O’Connor noted receiving this patent in Japan for the company’s proprietary immunotherapy product candidate, ADXS-HPV, to be used in treating patients with late-stage cervical cancer is an important milestone.
"This expands our patent portfolio which already has over 40 patents issued and over 40 patents pending worldwide.
"With licensing agreements established in Asia, with Global BioPharma, and India, with Biocon Ltd., Advaxis is positioned for global development and commercialization of our immunotherapies to treat cervical cancer.
"Expanding the protection of our intellectual property is a major component of this strategy," O’Connor added.